Literature DB >> 34604868

Meibum Lipid Composition and Conformation in Parkinsonism.

Solomon Blinchevsky1, Aparna Ramasubramanian2, Douglas Borchman1, Shanzeh Sayied1, Krithika Venkatasubramanian1.   

Abstract

PURPOSE: Patients with Parkinson's disease (PD) exhibit unstable tear films. Tear film lipid composition and structure are related to tear film stability and dry eye and tear lipids have not been characterized in people with PD. The aim of this study is to characterize Meibum tear lipids in donors with PD using 1H-NMR and infrared spectroscopy.
METHODS: Three cohorts were compared: meibum from donors with PD (Mp) n = 10, meibum from donors with PD and dry eye (Mpd) n = 3, meibum from donors without PD (Mn) n = 29.
RESULTS: There were no significant differences, P > 0.05, in hydrocarbon branching for Mp compared with Mn. Mn contained twice as much cholesteryl esters compared with Mp, P < 0.0001. The cooperativity of the phase transition was significantly 37% lower for Mp compared with Mn, P < 0.0001. Mpd was much more ordered (stiffer) with compared with Mp and Mn, P < 0.0001.
CONCLUSION: Changes in meibum lipid composition and structure could be a marker for and/or contribute to increase the susceptibility of dry eye in patients with PD. A less cooperative phase transition for Mp compared with Mn indicates that Mp was more heterogeneous and/or contained more contaminants than Mn. The data support the idea that more ordered lipid contributes to dry eye.

Entities:  

Keywords:  Dry Eye; Infrared Spectroscopy; Lipids; Meibum; NMR Spectroscopy; Parkinson’s Disease

Year:  2021        PMID: 34604868      PMCID: PMC8485155     

Source DB:  PubMed          Journal:  EC Ophthalmol


  30 in total

1.  Case-control study of blink rate in Parkinson's disease under different conditions.

Authors:  Emily Fitzpatrick; Norman Hohl; Peter Silburn; Cullen O'Gorman; Simon A Broadley
Journal:  J Neurol       Date:  2011-10-08       Impact factor: 4.849

Review 2.  Epidemiology of Parkinson's disease.

Authors:  Ole-Bjørn Tysnes; Anette Storstein
Journal:  J Neural Transm (Vienna)       Date:  2017-02-01       Impact factor: 3.575

Review 3.  Structure-function relationship of tear film lipid layer: A contemporary perspective.

Authors:  Georgi As Georgiev; Petar Eftimov; Norihiko Yokoi
Journal:  Exp Eye Res       Date:  2017-10       Impact factor: 3.467

4.  Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations.

Authors:  Gary N Foulks; Douglas Borchman; Marta Yappert; Sung-Hye Kim; John W McKay
Journal:  Cornea       Date:  2010-07       Impact factor: 2.651

5.  Corneal sensitivity, blink rate, and corneal nerve density in progressive supranuclear palsy and Parkinson disease.

Authors:  Vandana C Reddy; Sanjay V Patel; David O Hodge; Jacqueline A Leavitt
Journal:  Cornea       Date:  2013-05       Impact factor: 2.651

6.  Ophthalmologic features of Parkinson's disease.

Authors:  V Biousse; B C Skibell; R L Watts; D N Loupe; C Drews-Botsch; N J Newman
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

7.  13C and 1H NMR ester region resonance assignments and the composition of human infant and child meibum.

Authors:  Douglas Borchman; Marta C Yappert; Sarah E Milliner; Diana Duran; Gregory W Cox; Ryan J Smith; Rahul Bhola
Journal:  Exp Eye Res       Date:  2013-05-01       Impact factor: 3.467

8.  Differential scanning calorimetric evaluation of human meibomian gland secretions and model lipid mixtures: transition temperatures and cooperativity of melting.

Authors:  Hua Lu; Jadwiga C Wojtowicz; Igor A Butovich
Journal:  Chem Phys Lipids       Date:  2013-04-08       Impact factor: 3.329

9.  Structural Differences in Meibum From Teenagers Without and With Dry Eye and Allogeneic Hematologic Stem Cell Transplantations.

Authors:  Aparna Ramasubramanian; Douglas Borchman
Journal:  J Pediatr Hematol Oncol       Date:  2020-03       Impact factor: 1.170

10.  Schrimer test in Parkinson's disease.

Authors:  O Y Kwon; S H Kim; J H Kim; M H Kim; M K Ko
Journal:  J Korean Med Sci       Date:  1994-06       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.